A chronic multiple ascending dose phase Ib trial of Coversin in healthy volunteers

Trial Profile

A chronic multiple ascending dose phase Ib trial of Coversin in healthy volunteers

Recruiting
Phase of Trial: Phase I

Latest Information Update: 05 Dec 2016

At a glance

  • Drugs Coversin (Primary)
  • Indications Haemolytic uraemic syndrome; Paroxysmal nocturnal haemoglobinuria
  • Focus Adverse reactions
  • Most Recent Events

    • 05 Dec 2016 Results published in an Akari Therapeutics media release.
    • 12 Sep 2016 According to an Akari Therapeutics media release, the US FDA granted an orphan drug designation to coversin for the treatment of PNH.
    • 06 Jul 2016 According to Akari Therapeutics media release, this trial is being conducted at Hammersmith Medicines Research Ltd, in London.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top